Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H33ClN2O3 |
Molecular Weight | 493.037 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C(CC[N@+]1([O-])CC[C@](O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=KXVSBTJVTUVNPM-UKPNQBOSSA-N
InChI=1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3/t28-,32-
Loperamide Oxide is a prodrug of loperamide, an antidiarrheal agent, patented by Belgian pharmaceutical company Janssen Pharmaceutica N. V. as an antidiarrheal agent. Loperamide oxide is reduced to loperamide and has the same antisecretory potency as loperamide in jejunum and colon. In clinical trials, Loperamide oxide provides a safe and effective treatment for chronic diarrhea associated with Crohn's disease. Loperamide Oxide is used in the Netherlands for the treatment of acute diarrhea in adults under brand name Arestal.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0055114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7628301 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8529776
1 or 2 mg after passage of each unformed stool for 1-week
The mean daily dose of loperamide oxide was 2.7 mg.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A07DA05
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NG66S4H2RL
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
100000082027
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
DTXSID80883171
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
SUB27172
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
6139
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
SUB08573MIG
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
C174757
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
1370065
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY | |||
|
106900-12-3
Created by
admin on Fri Dec 15 18:51:11 GMT 2023 , Edited by admin on Fri Dec 15 18:51:11 GMT 2023
|
PRIMARY |
METABOLITE ACTIVE (PRODRUG)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD